2nd Circ. Allows Takeda To Appeal Actos Antitrust Class Cert. <https://www.law360.com/competition/articles/2323185?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-10&read_main=1&nlsidx=0&nlaidx=5>
By Lauren Berg A split Second Circuit will allow Takeda Pharmaceuticals Co. to immediately appeal a New York federal judge's ruling certifying two classes of direct purchasers and end payors in consolidated antitrust actions accusing the company of unlawfully inflating the price of its diabetes treatment Actos by delaying the entry of generic alternatives. 3 documents attached | Read full article » <https://www.law360.com/competition/articles/2323185?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-10&read_more=1&nlsidx=0&nlaidx=5> | Save to favorites » <https://www.law360.com/competition/articles/2323185?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-10&read_later=1&nlsidx=0&nlaidx=5>
